ClinicalTrials.gg
Active, not recruitingNCT07217158Updated Nov 3, 2026

Role of ROS and cAMP-PKA Biomarkers in ADPKD

An observational study in Autosomal Dominant Polycystic Kidney Disease, sponsored by Mayo Clinic. Active, not recruiting at 1 site in United States. Open to participants aged 15 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Mayo Clinic · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
15 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Polycystic Kidney, Autosomal Dominant by Mayo Clinic — 4 open to participants now, 7 under way, none of them phase 3. Polycystic Kidney, Autosomal Dominant · Mayo Clinic.

Started
2023
the only one that year
Observational
9 of 15
3 open now
Registered
14th of 15
by date

Among the 15 studies in Polycystic Kidney, Autosomal Dominant by Mayo Clinic, this one is the only one that started in 2023, is one of 9 observational ones, and was the 14th registered.

Polycystic Kidney, Autosomal Dominant

185 studies on the registry are indexed under Polycystic Kidney, Autosomal Dominant; 42 are open to participants now.

Browse Polycystic Kidney, Autosomal Dominant studies →

Open to participants now

4 of the 15 studies in Polycystic Kidney, Autosomal Dominant by Mayo Clinic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 30 Polycystic Kidney, Autosomal Dominant studies recruiting now, 8 (27%) set no upper age limit and 19 (63%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.

This study: 15 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Polycystic Kidney, Autosomal Dominant by Mayo Clinic, or all of them as a file.
02

Study summary

The primary objective is to determine the prognostic value of markers of ROS and cAMP-PKA signaling to assess disease severity and progression in patients with ADPKD.

Read the detailed description

Individuals with ADPKD are born with normal renal function that is preserved for several decades. By the time the GFR starts to decline, most of the kidneys have been replaced by cysts. The median age of end-stage renal disease (ESRD) is 54 years for PKD1 and 74 years for PKD2, but the rate of disease progression varies widely among individuals. This variability, along with the maintenance of normal GFR until the late stages, represents a significant challenge for nephrologists in following these patients. It is difficult to predict disease progression or evaluate a new therapy based solely on renal function markers at an early stage. On the other hand, if new therapies are implemented when GFR starts to decline and most irreversible damage has occurred, they are less likely to be effective. Hence, identifying robust, early disease biomarkers predictive of GFR decline and disease progression is crucial.

The improvement of imaging techniques over the years has provided insights into the natural history of the disease and facilitated the observation of its structural progression. The Consortium for Radiologic Imaging Studies of PKD (CRISP) study has shown that in patients with ADPKD, the increase in kidney and cyst volumes directly correlates with GFR decline, underscoring the potential of TKV to monitor disease progression and as a primary or secondary endpoint in clinical trials for ADPKD. However, TKV has limitations as a biomarker, as it is fairly crude and does not fully capture the pathophysiological processes underlying the development and progression of the disease. Therefore, biomarkers related to the underlying molecular mechanisms may detect renal injury before permanent anatomical damage occurs.

The investigators' broad objective is to determine the value of NOX4, as well as surrogate markers for ROS, mitochondrial injury, and metabolic pathways, to assess disease severity and progression from early stages.

Participants in this study will have blood and urine samples collected to determine biomarkers of oxidative stress, antioxidant response, related metabolite levels, as well as kidney injury markers. In addition, an abdominal MRI will be performed to determine the patient's total kidney volume (TKV).

03

Conditions studied

  • Autosomal Dominant Polycystic Kidney Disease

Keywords

  • Autosomal Dominant Polycystic Kidney Disease (ADPKD)
  • Oxidative stress
  • Antioxidant response
  • Mitochondria injury
04

Who can participate

Ages eligible
15 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Male and female patients with a previous diagnosis of ADPKD that meet the inclusion criteria.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female subjects 15 - 70 years of age
  • Previous diagnosis of ADPKD (based on Ravine et al. criteria)
  • Class 1 A-E according to imaging classification
  • estimated > 45 mL/min/1.73 m2 (CKD-EPI)
  • Ability to provide written,

Exclusion criteria

Exclusion Criteria:

  • Class 2, according to imaging classification
  • A concomitant systemic disease affecting the kidney
  • Diabetes mellitus
  • Predicted urine protein excretion in >1 g/24 hrs. and or abnormal urinalysis
  • Use of antioxidants, i.e., vitamins, Nrf2 activators
  • Patients who are part of an interventional study or taking tolvaptan
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (actual)
Patient registry
No
Biospecimen retention
Samples without dna
06

What researchers measure

Primary outcomes

  1. Change in height adjusted Total kidney volume (htTKV)

    TKV determined by MRI

    Time frame: Baseline to 24 months

  2. Change in eGFR

    eGFR estimated by CKD-EPI

    Time frame: Baseline to 24 months

  3. Baseline concentration of: NOX4, biochemical markers related to ROS, mitochondrial injury and metabolites as predictors of change in TKV and eGFR

    Biochemical markers determined by ELISA and/or biochemical assays, PCR, TKV determined by MRI, eGFR estimated by CKD-EPI.

    Time frame: Baseline to 24 months

Secondary outcomes

  1. Change in concentration of: NOX4, biochemical markers related to ROS, mitochondrial injury and metabolites

    Biochemical markers determined by ELISA and/or biochemical assays, PCR,

    Time frame: Baseline to 24 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2023 (actual). Primary completion is estimated for Mar 2027, 44 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 13, 2025
First posted
Oct 15, 2025
StartActual
Jul 1, 2023
Primary completionEst.
Mar 31, 2027
CompletionEst.
Jun 30, 2027
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07217158
Lead sponsor
Mayo Clinic
Collaborators
United States Department of Defense
Responsible party
Maria V. Irazabal Mira (Principal Investigator, Mayo Clinic) — Principal investigator
First posted
Oct 15, 2025
Start date
Jul 1, 2023
Primary completion
Mar 31, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Nov 3, 2026

Study contacts

Maria V. Irazabal, M.D., Ph.D.
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion